<?xml version="1.0" ?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.3 20210610//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">elife</journal-id>
<journal-id journal-id-type="publisher-id">eLife</journal-id>
<journal-title-group>
<journal-title>eLife</journal-title>
</journal-title-group>
<issn publication-format="electronic" pub-type="epub">2050-084X</issn>
<publisher>
<publisher-name>eLife Sciences Publications, Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">99084</article-id>
<article-id pub-id-type="doi">10.7554/eLife.99084</article-id>
<article-id pub-id-type="doi" specific-use="version">10.7554/eLife.99084.1</article-id>
<article-version-alternatives>
<article-version article-version-type="publication-state">reviewed preprint</article-version>
<article-version article-version-type="preprint-version">1.2</article-version>
</article-version-alternatives>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology and Inflammation</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>IL-2 enhances effector function but suppresses follicular localization of CD8<sup>+</sup> T cells in chronic infection</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Chen</surname>
<given-names>Yaping</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="author-notes" rid="n1">9</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" corresp="yes">
<name>
<surname>Zhou</surname>
<given-names>Pengcheng</given-names>
</name>
<email>pzhou@rockefeller.edu</email>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a6">6</xref>
<xref ref-type="author-notes" rid="n1">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gubser</surname>
<given-names>Patrick Marc</given-names>
</name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leong</surname>
<given-names>Yew Ann</given-names>
</name>
<xref ref-type="aff" rid="a1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Jing</given-names>
</name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Yunbo</given-names>
</name>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Makota</surname>
<given-names>Fadzai Victor</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pazhouhandeh</surname>
<given-names>Mehrdad</given-names>
</name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zheng</surname>
<given-names>Ting</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yunis</surname>
<given-names>Joseph</given-names>
</name>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Zhanguo</given-names>
</name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kallies</surname>
<given-names>Axel</given-names>
</name>
<email>axel.kallies@unimelb.edu.au</email>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1721-8922</contrib-id>
<name>
<surname>Yu</surname>
<given-names>Di</given-names>
</name>
<email>di.yu@uq.edu.au</email>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a3">3</xref>
<xref ref-type="aff" rid="a4">4</xref>
<xref ref-type="aff" rid="a8">8</xref>
<xref ref-type="corresp" rid="cor1">10</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Department of Biochemistry, School of Biomedical Sciences, Biomedical Discovery Institute, Monash University</institution>, Clayton, Victoria, <country>Australia</country></aff>
<aff id="a2"><label>2</label><institution>Oujiang Laboratory (Zhejiang Lab for Regenerative Medicine, Vision and Brain Health)</institution>, Wenzhou, Zhejiang, P.R. <country>China</country></aff>
<aff id="a3"><label>3</label><institution>Immunology and Infectious Disease Division, John Curtin School of Medical Research, The Australian National University</institution>, Canberra, Australian Capital Territory, <country>Australia</country></aff>
<aff id="a4"><label>4</label><institution>Frazer Institute, Faculty of Medicine, The University of Queensland</institution>, Brisbane, Queensland, <country>Australia</country></aff>
<aff id="a5"><label>5</label><institution>The Peter Doherty Institute for Infection and Immunity, Department of Microbiology and Immunology, The University of Melbourne</institution>, Parkville, Victoria, <country>Australia</country></aff>
<aff id="a6"><label>6</label><institution>Department of Rheumatology &amp; Immunology, Peking University People’s Hospital</institution>, Beijing, <country>China</country></aff>
<aff id="a7"><label>7</label><institution>Laboratory of Immunology for Environment and Health, Shandong Analysis and Test Center, Qilu University of Technology (Shandong Academy of Sciences)</institution>, Jinan, Shandong, <country>China</country></aff>
<aff id="a8"><label>8</label><institution>Ian Frazer Centre for Children’s Immunotherapy Research, Children’s Health Research Centre, Faculty of Medicine, The University of Queensland</institution>, Brisbane, Queensland, <country>Australia</country></aff>
</contrib-group>
<contrib-group content-type="section">
<contrib contrib-type="editor">
<name>
<surname>Lauvau</surname>
<given-names>Gregoire</given-names>
</name>
<role>Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Albert Einstein College of Medicine</institution>
</institution-wrap>
<city>Bronx</city>
<country>United States of America</country>
</aff>
</contrib>
<contrib contrib-type="senior_editor">
<name>
<surname>Taniguchi</surname>
<given-names>Tadatsugu</given-names>
</name>
<role>Senior Editor</role>
<aff>
<institution-wrap>
<institution>University of Tokyo</institution>
</institution-wrap>
<city>Tokyo</city>
<country>Japan</country>
</aff>
</contrib>
</contrib-group>
<author-notes>
<fn id="n1" fn-type="equal"><label>9</label><p>These authors contributed equally</p></fn>
<corresp id="cor1"><label>10</label>Lead corresponding author</corresp>
</author-notes>
<pub-date date-type="original-publication" iso-8601-date="2024-08-16">
<day>16</day>
<month>08</month>
<year>2024</year>
</pub-date>
<volume>13</volume>
<elocation-id>RP99084</elocation-id>
<history>
<date date-type="sent-for-review" iso-8601-date="2024-05-02">
<day>02</day>
<month>05</month>
<year>2024</year>
</date>
</history>
<pub-history>
<event>
<event-desc>Preprint posted</event-desc>
<date date-type="preprint" iso-8601-date="2024-05-04">
<day>04</day>
<month>05</month>
<year>2024</year>
</date>
<self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.05.02.592184"/>
</event>
</pub-history>
<permissions>
<copyright-statement>© 2024, Chen et al</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Chen et al</copyright-holder>
<ali:free_to_read/>
<license xlink:href="https://creativecommons.org/licenses/by/4.0/">
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="elife-preprint-99084-v1.pdf"/>
<abstract>
<title>Summary</title><p>Cytotoxic CD8<sup>+</sup> T cells, essential in combating viral infections and cancer, become dysfunctional from prolonged antigen exposure. Precursors of exhausted T (T<sub>PEX</sub>) cells are pivotal in sustaining immune responses in chronic diseases and mediating immunotherapy efficacy. They also control viral infection within B-cell follicles, facilitated by CXCR5 expression. How cytokines regulate T<sub>PEX</sub> cell fate and follicular entry is not well understood. We reveal that IL-2 treatment enhances CD8<sup>+</sup> T cell effector functions in chronic LCMV infection but hinders CXCR5<sup>+</sup> T<sub>PEX</sub> cell formation and infection control within B-cell follicles. Mechanistically, IL-2 suppresses T<sub>PEX</sub> cell differentiation in a STAT5 and BLIMP1-dependent manner. Using an IL-2 fusion protein targeting CD122, we shifted the differentiation towards CX3CR1<sup>+</sup> T cells with increased effector function. Clinical observations with low-dose IL-2 in autoimmune disease confirmed IL-2’s inhibitory effect on CXCR5<sup>+</sup> T<sub>PEX</sub> cells, underscoring IL-2’s crucial regulatory role and therapeutic potential in modulating T<sub>PEX</sub> and effector T cell generation.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords</title>
<kwd>Interleukin-2</kwd>
<kwd>LCMV</kwd>
<kwd>follicular infection</kwd>
<kwd>T<sub>PEX</sub></kwd>
<kwd>CXCR5</kwd>
<kwd>STAT5</kwd>
</kwd-group>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Correction of author affiliations and contributions
Correction of figure references in the text.</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>CD8<sup>+</sup> T cells play a critical role in eliminating virally infected and malignant cells. In chronic infection and cancer, antigen-specific CD8<sup>+</sup> T cells persistently exposed to antigen gradually reduce their ability to produce effector cytokines and proliferative capacity. This process is paralleled by the upregulation of inhibitory receptors or checkpoints such as programmed cell death protein 1 (PD-1), T cell immunoglobulin and mucin domain 3 (TIM-3) and lymphocyte-activation gene 3 (LAG3). Although such cellular reprogramming is necessary to restrain CD8<sup>+</sup> T cells-mediated immunopathology, reduced functionality in CD8<sup>+</sup> T cells impairs the clearance of infection or prevention of tumor growth. This process is referred to as T cell exhaustion (<xref ref-type="bibr" rid="c4">Blank et al., 2019</xref>; <xref ref-type="bibr" rid="c14">Hashimoto et al., 2018</xref>; <xref ref-type="bibr" rid="c35">McLane et al., 2019</xref>).</p>
<p>PD-1<sup>+</sup> exhausted CD8<sup>+</sup> T cells are heterogenous and contain a population of cells known as progenitors or precursors of exhausted T (T<sub>PEX</sub>) cells. These cells retain the capacity to self-renew while also giving rise to exhausted effector T (T<sub>EX</sub>) cells as we and others have shown (<xref ref-type="bibr" rid="c16">He et al., 2016b</xref>; <xref ref-type="bibr" rid="c21">Im et al., 2016</xref>; <xref ref-type="bibr" rid="c28">Leong et al., 2016</xref>; <xref ref-type="bibr" rid="c47">Utzschneider et al., 2016</xref>; <xref ref-type="bibr" rid="c50">Wu et al., 2016</xref>). T<sub>PEX</sub> cells also mediate the response to immune checkpoint blockade (ICB) therapies that inhibit PD-1/PD-Ligand 1 (PD-L1) interactions and thus amplify anti-viral and anti-tumor immunity in mice and humans (<xref ref-type="bibr" rid="c10">Eberhardt et al., 2021</xref>; <xref ref-type="bibr" rid="c18">Huang et al., 2022</xref>; <xref ref-type="bibr" rid="c21">Im et al., 2016</xref>; <xref ref-type="bibr" rid="c42">Siddiqui et al., 2019</xref>; <xref ref-type="bibr" rid="c47">Utzschneider et al., 2016</xref>). T<sub>PEX</sub> cells express the chemokine receptor CXCR5, which facilitates their migration to B-cell follicles where they contribute to the suppression of infection (<xref ref-type="bibr" rid="c16">He et al., 2016b</xref>; <xref ref-type="bibr" rid="c28">Leong et al., 2016</xref>). This is important as B-cell follicles act as reservoirs for certain viruses, such as Epstein–Barr virus (EBV) in memory B cells and Human Immunodeficiency Virus (HIV) in follicular helper T (T<sub>FH</sub>) cells (<xref ref-type="bibr" rid="c8">Collins et al., 2023</xref>; <xref ref-type="bibr" rid="c28">Leong et al., 2016</xref>; <xref ref-type="bibr" rid="c36">Mylvaganam et al., 2017</xref>; <xref ref-type="bibr" rid="c38">Petrovas et al., 2017</xref>). Therefore, CXCR5-expressing T<sub>PEX</sub> cells are critical in suppressing the infection in B-cell follicles (<xref ref-type="bibr" rid="c55">Yu and Ye, 2018</xref>).</p>
<p>T cell exhaustion is controlled by a network of transcriptional regulators induced by T cell receptor (TCR) stimulation-induced transcription factors, in particular NFATC1, TOX and IRF4 drive the sustained expression of inhibitory receptors and contribute to the downregulation of effector function (<xref ref-type="bibr" rid="c1">Alfei et al., 2019</xref>; <xref ref-type="bibr" rid="c26">Khan et al., 2019</xref>; <xref ref-type="bibr" rid="c32">Man et al., 2017</xref>; <xref ref-type="bibr" rid="c33">Martinez et al., 2015</xref>; <xref ref-type="bibr" rid="c40">Scott et al., 2019</xref>; <xref ref-type="bibr" rid="c41">Seo et al., 2019</xref>; <xref ref-type="bibr" rid="c53">Yao et al., 2019</xref>). The generation and maintenance of T<sub>PEX</sub> cells, on the other hand, are specifically controlled by transcription factors such as TCF1, MYB, ID3 and BCL6 while T<sub>EX</sub> cells differentiation is promoted by BLIMP1(<xref ref-type="bibr" rid="c12">Gautam et al., 2019</xref>; <xref ref-type="bibr" rid="c16">He et al., 2016b</xref>; <xref ref-type="bibr" rid="c21">Im et al., 2016</xref>; <xref ref-type="bibr" rid="c28">Leong et al., 2016</xref>; <xref ref-type="bibr" rid="c46">Tsui et al., 2022</xref>; <xref ref-type="bibr" rid="c47">Utzschneider et al., 2016</xref>; <xref ref-type="bibr" rid="c50">Wu et al., 2016</xref>). However, extracellular signals that regulate T<sub>PEX</sub> and T<sub>EX</sub> cell differentiation and maintenance are less understood. We and others have shown that TGFβ plays a key role in maintaining T<sub>PEX</sub> cell function and identity (<xref ref-type="bibr" rid="c11">Gabriel et al., 2021</xref>; <xref ref-type="bibr" rid="c17">Hu et al., 2022</xref>; <xref ref-type="bibr" rid="c31">Ma et al., 2022</xref>). Furthermore, both T<sub>FH</sub> cells-derived cytokine interleukin-21 (IL-21) and the alarmin IL-33 are necessary to maintain T<sub>PEX</sub> cells and sustain effector CD8<sup>+</sup> T cell function in chronic infection (<xref ref-type="bibr" rid="c34">Marx et al., 2023</xref>; <xref ref-type="bibr" rid="c54">Yu et al., 2022</xref>; <xref ref-type="bibr" rid="c56">Zander et al., 2022</xref>). Finally, IL-2, in combination with ICB, was shown to direct T<sub>PEX</sub> cells to generate transitory effector CD8<sup>+</sup>T cells and improve antiviral and antitumor activities (<xref ref-type="bibr" rid="c7">Codarri Deak et al., 2022</xref>; <xref ref-type="bibr" rid="c13">Hashimoto et al., 2022</xref>; <xref ref-type="bibr" rid="c39">Ren et al., 2022</xref>; <xref ref-type="bibr" rid="c45">Tichet et al., 2023</xref>; <xref ref-type="bibr" rid="c49">West et al., 2013</xref>). However, the precise function of IL-2 in regulating T cell exhaustion is not fully understood.</p>
<p>To better understand how IL-2 regulates T<sub>PEX</sub> cell differentiation and function, we investigated the impact and molecular mechanisms of treatment with IL-2 or a clinical-grade IL-2 fusion protein specifically targeting the IL-2 receptor β chain (CD122) in chronic LCMV infection. IL-2 treatment increased the generation of CX3CR1+ T<sub>EX</sub> cells with enhanced effector function without disrupting the self-renewal capacity of T<sub>PEX</sub> cells both in mouse and human. At the same time, IL-2 treatment resulted in downregulation of CXCR5 expression on T<sub>PEX</sub> cells, their exclusion from B-cell follicles and impaired viral clearance from these sites. Furthermore, increased IL-2 signaling during the early stages of the immune response strongly suppressed T<sub>PEX</sub> cell generation. Mechanistically, IL-2 exerted its effects in a STAT5– and BLIMP1-dependent manner. Overall, our data show that IL-2 treatment can broadly modulate the balance between effector T cells and T<sub>PEX</sub> cells and excert differential effects on viral clearance.</p>
</sec>
<sec id="s2">
<title>Results</title>
<sec id="s2a">
<title>IL-2 treatment promotes CD8<sup>+</sup> T effector expansion during chronic infection</title>
<p>IL-2 is an approved immunotherapeutic agent for cancer (<xref ref-type="bibr" rid="c9">Dutcher et al., 2014</xref>). It’s precise mechanism of action is not fully understood. To elucidate how IL-2 affects exhausted CD8<sup>+</sup> T cell maintenance and function, wild-type C57BL/6 mice were infected with LCMV Docile (10<sup>6</sup> plaque-forming units, PFU), which induces chronic infection and robust T cell exhaustion. Mice were treated with PBS or low-to-medium dose of recombinant human IL-2 (30,000 international units, IU (<xref ref-type="bibr" rid="c5">Blattman et al., 2003</xref>; <xref ref-type="bibr" rid="c15">He et al., 2016a</xref>; <xref ref-type="bibr" rid="c49">West et al., 2013</xref>)) daily from day 10 to 14 post-infection before analysis on day 15 (<xref rid="fig1" ref-type="fig">Figure 1A</xref>). IL-2 treatment elevated CD8<sup>+</sup> T cell numbers and increased CD8<sup>+</sup>/CD4<sup>+</sup> T cell ratios (<xref rid="fig1" ref-type="fig">Figure 1B</xref>). Furthermore, numbers of activated CD8<sup>+</sup> T cells (CD44<sup>high</sup>CD62L<sup>-</sup>) and their effector function as measured by Granzyme B expression were significantly enhanced by IL-2 treatment (<xref rid="fig1" ref-type="fig">Figure 1C</xref><bold>, D</bold>). In agreement with previous studies (<xref ref-type="bibr" rid="c5">Blattman et al., 2003</xref>; <xref ref-type="bibr" rid="c58">Zhou et al., 2021</xref>), we found that IL-2 treatment significantly increased both the frequencies and numbers of LCMV-specific CD8<sup>+</sup> T cells as measured by staining with H-2D<sup>b</sup> LCMV GP<sub>33</sub> tetramers (<xref rid="fig1" ref-type="fig">Figure 1E</xref>). We did not observe an expansion of regulatory (T<sub>REG</sub>) cells by this dose of IL-2 treatment (data not shown), presumably due to the high numbers of activated effector T cells (<xref ref-type="bibr" rid="c20">Humblet-Baron et al., 2016</xref>; <xref ref-type="bibr" rid="c58">Zhou et al., 2021</xref>). We next examined the impact of IL-2 treatment on the generation of TCF1<sup>+</sup>CXCR5<sup>+</sup> T<sub>PEX</sub> and TCF1<sup>-</sup>CXCR5<sup>-</sup> T<sub>EX</sub> cells. IL-2 treatment increased the total numbers of T<sub>EX</sub> cells by more than two-fold (<xref rid="fig1" ref-type="fig">Figure 1F</xref>). In contrast, IL-2 treatment reduced the frequencies of T<sub>PEX</sub> cells within GP<sub>33</sub> tetramer<sup>+</sup> CD8<sup>+</sup> T cells by more than two-fold although their numbers remained largely unchanged (<xref rid="fig1" ref-type="fig">Figure 1F</xref>). Overall, IL-2 treatment enhanced effector T cell expansion in chronic infection.</p>
<fig id="fig1" position="float" orientation="portrait" fig-type="figure">
<label>Figure 1.</label>
<caption><title>IL-2 treatment promotes CD8+ T effector expansion during chronic infection.</title><p>(<bold>A</bold>) Schematic showing C57BL/6 mice chronically infected with LCMV Docile and receiving intraperitoneal treatment of 30,000 IU recombinant human IL-2 daily from day 10 to 14 post infection, followed by the analyses on day 15. (<bold>B</bold>) Quantification showing CD4/CD8 ratio and the numbers of CD8<sup>+</sup> T cells in the spleen. Cells were gated on 7AAD<sup>-</sup> B220<sup>-</sup> TCRβ<sup>+</sup>CD8<sup>+</sup> or CD4<sup>+</sup> cells using flow cytometry. (<bold>C</bold>,<bold>D</bold>) Representative FACS plots and statistics showing CD44<sup>high</sup>CD62L<sup>low</sup> effector (C) and the expression of Granzyme B (D) in total CD8<sup>+</sup> T cells in mice treated with PBS or IL-2. (<bold>E, F</bold>) Representative FACS plots and quantification showing the frequencies and numbers of H-2Db LCMV GP<sub>33</sub> tetramer-specific CD8<sup>+</sup> T cells (E) and the frequencies and numbers of CXCR5<sup>-</sup>TCF1<sup>-</sup> T<sub>EX</sub> cells and CXCR5<sup>+</sup>TCF1<sup>+</sup> T<sub>PEX</sub> cells. Results are representative of two or three independent experiments (<italic>n</italic> = 4-5/group). Each dot represents one individual mouse. Student’s unpaired two-tailed t tests.</p></caption>
<graphic xlink:href="592184v2_fig1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2b">
<title>IL-2 alters tissue localization of CD8<sup>+</sup> T cells and viral reservoirs in chronic infection</title>
<p>Previous studies reported that a short period of IL-2 treatment, despite enhancing CD8<sup>+</sup> T effector function, was insufficient to significantly reduce viral loads (<xref ref-type="bibr" rid="c5">Blattman et al., 2003</xref>; <xref ref-type="bibr" rid="c58">Zhou et al., 2021</xref>). LCMV preferentially infects myeloid cells expressing high levels of α-Dystroglycan (α-DG), the cellular receptor for LCMV (<xref ref-type="bibr" rid="c27">Kunz et al., 2001</xref>; <xref ref-type="bibr" rid="c37">Oldstone and Campbell, 2011</xref>), but it also infects lymphocytes including CD4<sup>+</sup> T cells (<xref ref-type="bibr" rid="c28">Leong et al., 2016</xref>). Immunofluorescent microscopy of splenic tissue using the antibody (VL4) to LCMV nucleoprotein revealed that IL-2 treatment resulted in an altered distribution of VL4<sup>+</sup> LCMV reservoirs towards B220<sup>+</sup> B-cell follicles (<xref rid="fig2" ref-type="fig">Figure 2A</xref>). To examine whether IL-2 treatment influenced the distribution of virus in the B-cell follicle and the T-cell zone, we deployed a flow cytometry-based method previously developed (<xref ref-type="bibr" rid="c28">Leong et al., 2016</xref>). Treatment with IL-2, in a dose-dependent manner, reduced numbers of virus-infected CXCR5<sup>low</sup>CD44<sup>+</sup> non-T<sub>FH</sub> effector CD4<sup>+</sup> T cells, which primarily reside in the T-cell zone, whereas the numbers of virally infected CXCR5<sup>high</sup>CD44<sup>+</sup> T<sub>FH</sub> cells, which mostly reside in B-cell follicles, remained unchanged. As a consequence, the LCMV reservoir was biased towards the B-cell follicle, indicated by a two-fold increase in the ratio of infected T<sub>FH</sub>/non-T<sub>FH</sub> cells at the highest dose of IL-2 treatment (<xref rid="fig2" ref-type="fig">Figure 2B</xref>).</p>
<fig id="fig2" position="float" orientation="portrait" fig-type="figure">
<label>Figure 2.</label>
<caption><title>IL-2 alters tissue localization of CD8<sup>+</sup> T cells and viral reservoirs in chronic infection.</title><p>(<bold>A</bold>) C57BL/6 mice were chronically infected with LCMV Docile and received intraperitoneal treatment with IL-2 as in <xref rid="fig1" ref-type="fig">Figure 1A</xref>. Representative confocal images (left: low magnification, right: high magnification) and quantification of LCMV infected cells in the spleen. (<bold>B</bold>) C57BL/6 mice chronically infected with LCMV Docile and receiving intraperitoneal treatment of gradient doses of recombinant human IL-2 (10,000 – 100,000 IU) daily from day 10 to 14 post infection, followed by the analyses on day 15. FACS plot showing the gating of T<sub>FH</sub> and non-T<sub>FH</sub> cells in CD4<sup>+</sup> T cells (left), and quantification of virus-infected (VL4<sup>+</sup>) T<sub>FH</sub> and non-T<sub>FH</sub> cells in each group (right). (<bold>C</bold>, <bold>D</bold>) In the same experiment as (A), histograms showing the expression of CXCR5 on GP<sub>33</sub> tetramer-specific CXCR5<sup>+</sup> CD8<sup>+</sup> T cells (C) and representative images (left) and quantification (right) of CD8<sup>+</sup> T cells in B-cell follicles (D). (<bold>E</bold>) Representative FACS plots (left) and quantification (right) showing the expression of CXCR5<sup>+</sup> on OT-I CD8<sup>+</sup> T cells, co-cultured with splenocytes pulsed with the SINFEKL peptide (1 µM) and indicated cytokines: TGFβ (10 ng/mL), IL-6 (100 ng/mL) and IL-2 (500 I.U./mL). Results are representative of at least two independent experiments. Each dot represents one image count (A, D), one individual mouse (B), or one culture (E). Student’s unpaired two-tailed t tests.</p></caption>
<graphic xlink:href="592184v2_fig2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>T<sub>PEX</sub> cells that express CXCR5 have access to the B-cell follicle and contribute to viral control (<xref ref-type="bibr" rid="c8">Collins et al., 2023</xref>; <xref ref-type="bibr" rid="c28">Leong et al., 2016</xref>; <xref ref-type="bibr" rid="c38">Petrovas et al., 2017</xref>). The altered distribution of LCMV reservoirs, however, suggested that IL-2 treatment prevents access of CD8<sup>+</sup> T cells to B-cell follicles. Indeed, IL-2 treatment significantly reduced CXCR5 expression on T<sub>PEX</sub> cells (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). In line with this observation, immunofluorescent imaging of splenic tissue sections revealed a drastic reduction of CD8<sup>+</sup> T cells in the B-cell follicles in IL-2-treated mice compared with that of PBS-treated control mice (<xref rid="fig2" ref-type="fig">Figure 2D</xref>).</p>
<p>Systemic administration of IL-2 may control CD8<sup>+</sup> T cell activation and differentiation directly or indirectly. We therefore assessed the direct impact of IL-2 <italic>in vitro</italic>. Stimulation of human CD8<sup>+</sup> T cells with anti-CD3/CD28 and cytokines TGFβ, IL-12, and IL-23 was shown to promote CXCR5 expression (<xref ref-type="bibr" rid="c36">Mylvaganam et al., 2017</xref>). In lijne with that observation, we and others found that TGFβ supported T<sub>PEX</sub> cell generation and maintenance (<xref ref-type="bibr" rid="c11">Gabriel et al., 2021</xref>; <xref ref-type="bibr" rid="c17">Hu et al., 2022</xref>; <xref ref-type="bibr" rid="c31">Ma et al., 2022</xref>). We therefore optimized a culture condition whereby naïve mouse OT-I CD8<sup>+</sup> T cells that carry a transgenic TCR-specific to ovalbumin (OVA) antigen were stimulated with splenocytes pulsed with SIINFEKL peptide in the presence or absence of TGFβ and IL-6, with or without IL-2. The combination of TGFβ and IL-6 induced CXCR5 expression on OT-I T cells. In contrast, the addition of IL-2 in the culture diminished CXCR5 expression by about three-fold (<xref rid="fig2" ref-type="fig">Figure 2E</xref>). Overall, these results suggest that IL-2 induces signaling that favors the generation of CXCR5<sup>-</sup> T<sub>EX</sub> cells over CXCR5<sup>+</sup> T<sub>PEX</sub> cells in CD8 T cells.</p>
</sec>
<sec id="s2c">
<title>An IL-2-STAT5-BLIMP1 axis regulates the balance of effector and T<sub>PEX</sub> generation</title>
<p>To better understand the impact of IL-2 on T<sub>PEX</sub> and T<sub>EX</sub> cell generation, we performed Gene Set Enrichment Analysis (GSEA) of CXCR5<sup>+</sup> T<sub>PEX</sub> cells compared to CXCR5<sup>-</sup> T<sub>EX</sub> cells (<xref ref-type="bibr" rid="c28">Leong et al., 2016</xref>). This analysis indicated downregulation of IL-2-STAT5 signaling in CXCR5<sup>+</sup> T<sub>PEX</sub> cells (<xref ref-type="fig" rid="figs1">Suppl. Figure 1A</xref>), suggesting that IL-2 negatively impacts the generation or function of CXCR5<sup>+</sup> T<sub>PEX</sub> cells. The IL-2 receptor is a heterotrimeric protein complex composed of three subunits: the α subunit CD25 encoded by <italic>Il2ra</italic>, the β subunit CD122 encoded by <italic>Il2rb</italic>, and the common γ chain CD132 encoded by <italic>Il2rg</italic> (<xref ref-type="bibr" rid="c6">Boyman and Sprent, 2012</xref>). Transcriptomic analysis indicated that <italic>Il2ra</italic> and <italic>Il2rb</italic> were lower in CXCR5<sup>+</sup> T<sub>PEX</sub> population, whereas <italic>Il7r</italic> was higher, compared with CXCR5<sup>-</sup> T<sub>EX</sub> cells (<xref ref-type="fig" rid="figs1">Suppl. Figure 1B,C</xref>). Flow cytometric analysis showed that the expression of CD122 on CXCR5<sup>+</sup> T<sub>PEX</sub> was significantly lower than that on CXCR5<sup>-</sup> T<sub>EX</sub> cells, while CD25 protein was minimally expressed on both populations (<xref rid="fig3" ref-type="fig">Figure 3A</xref>). Notably, the treatment of IL-2 in mice with LCMV infection pronouncedly increased CD122 expression and modestly increased CD25 expression on T<sub>PEX</sub> cells, whereas such effects were not observed in T<sub>EX</sub> cells (<xref rid="fig3" ref-type="fig">Figure 3B</xref> and <xref ref-type="fig" rid="figs1">Suppl. Figure 1D</xref>).</p>
<fig id="fig3" position="float" orientation="portrait" fig-type="figure">
<label>Figure 3.</label>
<caption><title>An IL-2-STAT5-BLIMP1 axis regulates the balance of effector and T<sub>PEX</sub> generation.</title><p>(<bold>A-C</bold>) C57BL/6 mice were chronically infected with LCMV Docile and received intraperitoneal treatment with IL-2 as in <xref rid="fig1" ref-type="fig">Figure 1A</xref>. Quantification of the expression of CD122 and CD25 between CXCR5<sup>+</sup> T<sub>PEX</sub> cells and CXCR5<sup>-</sup> T<sub>EX</sub> cells (A). The comparison of the expression of CD122 and CD25 on CXCR5<sup>+</sup> T<sub>PEX</sub> cells or CXCR5<sup>-</sup> T<sub>EX</sub> cells between PBS treated and IL-2 treated mice (B). The comparison of the expression of pSTAT5 in CXCR5<sup>+</sup> T<sub>PEX</sub> cells or CXCR5<sup>-</sup> T<sub>EX</sub> cells between PBS treated and IL-2 treated mice (C). (<bold>D-F</bold>) Schematic (D) showing the overexpression of constitutive active STAT5b (STAT5b-CA) in P14 cells, followed by the adoptive transfer in congenically marked recipient mice with chronical LCMV Docile infection. Representative FACS plots (left) and quantifications (right) of the frequencies of P14 cells in total CD8<sup>+</sup> T cells (E) and the frequencies of CXCR5<sup>+</sup> T<sub>PEX</sub> cells in P14 cells (F). (<bold>G</bold>, <bold>H</bold>) Schematic of the generation of bone marrow chimera mice carrying T cell specific deletion of BLIMP1 (encoded by <italic>Prdm1</italic>), followed with chronic LCMV Docile infection and IL-2 treatment (i.p. 30,000 I.U. daily from day 10 to 14 post-infection) (G). Representative FACS plots and quantifications showing the frequencies of CXCR5<sup>+</sup> T<sub>PEX</sub> cells in CD44<sup>+</sup> CD8<sup>+</sup> T cells (H). Results are representative of two or three independent experiments (<italic>n</italic> = 4-5/group). Each dot represents one individual mouse. Student’s unpaired two-tailed t tests. N.S., statistically not significant.</p></caption>
<graphic xlink:href="592184v2_fig3.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs1" position="float" orientation="portrait" fig-type="figure">
<label>Suppl. Figure 1.</label>
<caption><title>Comparison of IL-2-STAT5 signaling and IL-2 receptors between CXCR5<sup>+</sup> T<sub>PEX</sub> cells and CXCR5<sup>-</sup> T<sub>EX</sub> cells.</title><p>(<bold>A-C</bold>) Purified CXCR5<sup>+</sup> T<sub>PEX</sub> and CXCR5<sup>−</sup> T<sub>EX</sub> P14 cells from host C57BL/6 mice at day 8 post LCMV (DOCILE) infection underwent RNA-seq to generate transcriptomes as described previously (<xref ref-type="bibr" rid="c28">Leong et al., 2016</xref>). Gene set enrichment analyses showing the downregulation of IL-2-STAT5 signalling in CXCR5+ T<sub>PEX</sub> cells (A). Heatmaps (B) and quantification (C) showing the expression of indicated cytokine receptor genes.</p><p>(<bold>D</bold>) C57BL/6 mice were chronically infected with LCMV Docile and receiving intraperitoneal treatment of IL-2 as in <xref rid="fig1" ref-type="fig">Figure 1A</xref>. FACS plots showing the gating of CXCR5<sup>+</sup> T<sub>PEX</sub> cells and CXCR5<sup>−</sup> T<sub>EX</sub> populations in LCMV-specific GP<sub>33</sub> tetramer<sup>+</sup> CD8<sup>+</sup> T cells (left) and histograms showing the expression of CD122 and CD25 on indicated populations.</p></caption>
<graphic xlink:href="592184v2_figs1.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<p>The phosphorylation of STAT5 (pSTAT5) is a major signaling event induced by IL-2 (<xref ref-type="bibr" rid="c6">Boyman and Sprent, 2012</xref>). IL-2 treatment increased the pSTAT5 level in CXCR5<sup>+</sup> T<sub>PEX</sub> cells but not in CXCR5<sup>-</sup> T<sub>PEX</sub> cells (<xref rid="fig3" ref-type="fig">Figure 3C</xref>). To directly test the impact of STAT5 signaling, we transduced CD45.2 TCR transgenic P14 T cells that are specific for the LCMV GP<sub>33-41</sub> epitope with the retrovirus expressing a constitutively activated version of STAT5b (STAT5b-CA) or an empty viral vector control (<xref ref-type="bibr" rid="c22">Johnston et al., 2012</xref>). Transduced P14 T cells were then transferred into congenically marked CD45.1 recipient mice followed by LCMV Docile infection (<xref rid="fig3" ref-type="fig">Figure 3D</xref>). Similar to the effects of IL-2 treatment and in line with a recent report (Beltra et al Immunity 2023), STAT5b-CA overexpression led to an increase in total P14 cells by about three-fold compared to controls (<xref rid="fig3" ref-type="fig">Figure 3E</xref>). Importantly, the constitutive activation of the STAT5 signaling in P14 cells favored the generation of CXCR5<sup>-</sup> T<sub>EX</sub> over CXCR5<sup>+</sup> T<sub>PEX</sub> cells <italic>in vivo</italic> (<xref rid="fig3" ref-type="fig">Figure 3F</xref>).</p>
<p>CXCR5<sup>+</sup> T<sub>FH</sub> cells and CXCR5<sup>+</sup> T<sub>PEX</sub> cells share a similar transcriptional program for their generation whereby both are promoted by transcription factors TCF1 and BCL6 and suppressed by BLIMP1 and ID2 (<xref ref-type="bibr" rid="c25">Kallies et al., 2020</xref>; <xref ref-type="bibr" rid="c48">Vinuesa et al., 2016</xref>). We and others previously reported that IL-2/STAT5 signaling induces the expression of B lymphocyte-induced maturation protein-1 (BLIMP1, encoded by <italic>Prdm1</italic>), a negative regulator of <italic>Cxcr5</italic> transcription (<xref ref-type="bibr" rid="c23">Johnston et al., 2009</xref>; <xref ref-type="bibr" rid="c28">Leong et al., 2016</xref>; <xref ref-type="bibr" rid="c51">Xin et al., 2016</xref>). We therefore examined the roles of BLIMP1 in regulating the differentiation of CXCR5<sup>+</sup> T<sub>PEX</sub> cells in response to IL-2. First, we generated mixed bone marrow chimeric mice containing cells from mice carrying a T cell-specific ablation of Blimp1 (<italic>Prdm1</italic><sup>flox/flox</sup><italic>Lck</italic><sup>Cre</sup>) and cells from congenically marked wildtype mice, mixed at a 1:1 ratio. These chimeras were infected with LCMV Docile, treated with IL-2 or PBS from day 10 to day 14 and analyzed on day 15 (<xref rid="fig3" ref-type="fig">Figure 3G</xref>). As expected, we observed larger proportions of CXCR5<sup>+</sup> T<sub>PEX</sub> cells in BLIMP1-deficient (∼30%) compared to control (∼15%) CD8<sup>+</sup> T cells. Notably, IL-2 treatment further reduced the CXCR5<sup>+</sup> T<sub>PEX</sub> cell percentages from ∼15% to ∼6% in control CD8<sup>+</sup> T cells but did not reduce T<sub>PEX</sub> cell frequencies in BLIMP1-deficient CD8<sup>+</sup> T cells, which remained as ∼30% (<xref rid="fig3" ref-type="fig">Figure 3H</xref>). Taken together, our results indicate that the IL-2-STAT5-BLIMP1 axis plays a critical role in regulating the generation of CXCR5<sup>+</sup> T<sub>PEX</sub> cells in response to IL-2 treatment in chronic infection.</p>
</sec>
<sec id="s2d">
<title>An IL-2 fusion protein regulates the balance of effector and T<sub>PEX</sub> cell generation</title>
<p>IL-2 fusion proteins that increase the half-life or bioavailability of IL-2 have recently been shown to be promising tools in cancer immunotherapy (<xref ref-type="bibr" rid="c2">Beltra et al., 2023</xref>; <xref ref-type="bibr" rid="c7">Codarri Deak et al., 2022</xref>; <xref ref-type="bibr" rid="c13">Hashimoto et al., 2022</xref>; <xref ref-type="bibr" rid="c45">Tichet et al., 2023</xref>). To specifically assess the role of the IL-2-CD122 axis in regulating the generation of T<sub>PEX</sub> cells, we examined the effects of a novel IL-2 fusion protein, ANV410, that selectively targets CD122. Consistent with the CD122-specific activity, treatment of naïve mice with ANV410 resulted in a dramatic expansion of CD44<sup>+</sup> memory CD8<sup>+</sup> T cells, and NK cells, without affecting T<sub>REG</sub> cells (<xref ref-type="fig" rid="figs1">Suppl. Figure 2</xref>). We next treated mice chronically infected with LCMV Docile (8-12 days post infection), which had received LCMV-specific P14 T cells (Regimen A, <xref rid="fig4" ref-type="fig">Figure 4A</xref>). Total CD8<sup>+</sup> as well as P14 T cells expanded substantially in response to ANV410 (<xref rid="fig4" ref-type="fig">Figure 4B</xref>). We also observed a significant increase in the percentage and numbers of CX3CR1<sup>+</sup> T<sub>EX</sub> cells (<xref rid="fig4" ref-type="fig">Figure 4C</xref>), which harbor the highest functional capacity among exhausted T cells (<xref ref-type="bibr" rid="c19">Hudson et al., 2019</xref>; <xref ref-type="bibr" rid="c57">Zander et al., 2019</xref>). Consistent with this observation, we also found larger numbers of P14 T cells expressing Granzyme B (<xref rid="fig4" ref-type="fig">Figure 4D</xref>). In contrast, the percentages of T<sub>PEX</sub> cells in P14 T cells declined while their numbers remained unchanged (<xref rid="fig4" ref-type="fig">Figure 4E</xref>), which was consistent with the results from IL-2 treatment (<xref rid="fig2" ref-type="fig">Figure 2E</xref>). To examine the effects of the IL-2 fusion protein on the generation of T<sub>PEX</sub> cells, we treated mice with ANV410 during the first 5 days post infection (Regimen B, <xref rid="fig4" ref-type="fig">Figure 4A</xref>). Strikingly, early ANV410 treatment dramatically impaired the expansion of P14 T cells (<xref rid="fig4" ref-type="fig">Figure 4F</xref>) and abrogated TPEX cell development almost completely both in the P14 and polyclonal PD-1<sup>+</sup> CD8 T cell compartment (<xref rid="fig4" ref-type="fig">Figure 4G</xref><bold>, H</bold>), suggesting that increased IL-2 signaling early during infection is detrimental to T<sub>PEX</sub> cell development and function.</p>
<fig id="fig4" position="float" orientation="portrait" fig-type="figure">
<label>Figure 4.</label>
<caption><title>An IL-2 fusion protein regulates the balance of effector and T<sub>PEX</sub> cell generation.</title><p>(<bold>A</bold>) Schematic showing P14 T cells being transferred into congenically marked mice, which were subsequently infected with LCMV Docile and treated with ANV410, a CD122-specific IL-2 fusion protein, three times every other day from day 8 to 12 post infection and analyzed on day 14 post infection (regimen 1, panels B-E) or from day 1 to 5 of infection and analyzed on day 7 post infection (regimen 2, panels F-H). (<bold>B</bold>) Quantifications of total CD8<sup>+</sup> T cells (left) or P14 cells (right) on day 14 post infection (regimen 1). (<bold>C</bold>) FACS plot showing the gating strategy for CX3CR1<sup>+</sup> T<sub>EX</sub> cells (left) and quantifications of percentages and numbers of CX3CR1<sup>+</sup> T<sub>EX</sub> cells in P14 cells on day 14 post infection (regimen 1). (<bold>D</bold>) Quantification showing percentages and expression levels of GzmB<sup>+</sup> P14 cells on day 14 post infection (regimen 1). (<bold>E</bold>) FACS plots showing the gating strategy for TCF1<sup>+</sup> T<sub>PEX</sub> cells (left) and quantification showing the percentages and numbers of TCF1<sup>+</sup> T<sub>PEX</sub> cells in P14 cells on day 14 post infection (regimen 1). (<bold>F</bold>) Quantification showing the percentages and numbers of P14 cells on day 7 post infection (regimen 2). (<bold>G</bold>) FACS plots showing the gating strategy for TCF1<sup>+</sup> T<sub>PEX</sub> cells (left) and quantification showing the percentages and numbers of TCF1<sup>+</sup> T<sub>PEX</sub> cells in P14 cells on day 7 post infection (regimen 2). (<bold>H</bold>) Quantification showing the percentages and numbers of TCF1<sup>+</sup> T<sub>PEX</sub> cells in endogenous PD-1<sup>+</sup> CD8<sup>+</sup> T cells on day 7 post infection (regimen 2). (<bold>I</bold>) Schematic of low-dose IL-2 therapy in patients with systemic lupus erythematosus (SLE). (<bold>J</bold>) Quantification showing the frequencies of CXCR5<sup>+</sup> T<sub>PEX</sub> in peripheral blood CD8<sup>+</sup> T cells in consecutive time points (left) or before and after the therapy (right). Each dot represents one individual mouse (B-H) or one individual patient (J). Student’s unpaired two-tailed t tests (B-H) and paired two-tailed t test (J).</p></caption>
<graphic xlink:href="592184v2_fig4.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
<fig id="figs2" position="float" orientation="portrait" fig-type="figure">
<label>Suppl. Figure 2.</label>
<caption><title>Treatment with a CD122-specific IL-2 fusion protein results in CD8 T cell and NK cell but not T<sub>REG</sub> cell expansion.</title><p>C57BL/6 mice were chronically infected with LCMV Docile and receiving intraperitoneal treatment of ANV410 as in <xref rid="fig4" ref-type="fig">Figure 4A</xref> (Regimen A).</p><p>(<bold>A</bold>) FACS plots (left) and quantifications (right) for total CD4<sup>+</sup> or CD8<sup>+</sup> T cells.</p><p>(<bold>B</bold>) Quantification for CD3<sup>-</sup>NK1.1<sup>+</sup> NK cells.</p><p>(<bold>C</bold>) Quantification for Foxp3<sup>+</sup> CD4<sup>+</sup> T<sub>REG</sub> cells.</p></caption>
<graphic xlink:href="592184v2_figs2.tif" mime-subtype="tiff" mimetype="image"/>
</fig>
</sec>
<sec id="s2e">
<title>IL-2 treatment reduces CXCR5<sup>+</sup> T<sub>PEX</sub> cells in humans</title>
<p>Finally, we asked whether IL-2 treatment in humans could regulate T<sub>PEX</sub> cells. We took advantage of immunological profiling data that we previously collected in a clinical trial of low-dose IL-2 therapy in patients with systemic lupus erythematosus (SLE). In this clinical trial, patients were treated with three two-week cycles of 1,000,000 IU recombinant human IL-2 every other day (<xref rid="fig4" ref-type="fig">Figure 4I</xref>) (<xref ref-type="bibr" rid="c15">He et al., 2016a</xref>). The results demonstrated that low-dose IL-2 treatment significantly reduced human CXCR5<sup>+</sup> T<sub>PEX</sub> cells in the blood after three cycles of low-dose IL-2 therapy (<xref rid="fig4" ref-type="fig">Figure 4J</xref>); this is in agreement with the observation of suppression of CXCR5 expression on CD8<sup>+</sup> T cells by IL-2 treatment in the mouse model of LCMV chronic infection (<xref rid="fig2" ref-type="fig">Figure 2C</xref>). Overall, our data in both mice and humans indicate that increased IL-2 signaling via CD122 during early stages of the infection can impair the generation of T<sub>PEX</sub> cells, while a short period of therapeutic IL-2 treatment at later stages of the infection increases the differentiation of effector cells from T<sub>PEX</sub> cells without impacting their self-renewal capacity.</p>
</sec>
</sec>
<sec id="s3">
<title>Discussion</title>
<p>Upon chronic antigen exposure, CD8<sup>+</sup> T cells upregulate the expression of inhibitory receptors including PD-1. PD-1<sup>+</sup> T cells in chronic infection are heterogenous, containing TCF1<sup>+</sup> T<sub>PEX</sub> cells that undergo self-renewal but also give rise to TCF1<sup>-</sup> T<sub>EX</sub> cells that lack long-term proliferative capacity (<xref ref-type="bibr" rid="c16">He et al., 2016b</xref>; <xref ref-type="bibr" rid="c18">Huang et al., 2022</xref>; <xref ref-type="bibr" rid="c21">Im et al., 2016</xref>; <xref ref-type="bibr" rid="c28">Leong et al., 2016</xref>; <xref ref-type="bibr" rid="c47">Utzschneider et al., 2016</xref>; <xref ref-type="bibr" rid="c50">Wu et al., 2016</xref>). Critically, T<sub>PEX</sub> cells mediate the proliferative burst in response to PD-1 immune checkpoint inhibition, which induces the differentiation of CX3CR1<sup>+</sup> effector-like T<sub>EX</sub> cells, which display the highest effector function and antiviral activity and closely correlate with positive response to therapeutic ICB in cancer (<xref ref-type="bibr" rid="c19">Hudson et al., 2019</xref>; <xref ref-type="bibr" rid="c52">Yan et al., 2018</xref>; <xref ref-type="bibr" rid="c57">Zander et al., 2019</xref>). Maintaining a balance between self-renewal, effector function and terminal exhaustion underlying by these functional subsets is essential to sustain cytotoxic killing while restraining immunopathology at the same time (<xref ref-type="bibr" rid="c4">Blank et al., 2019</xref>; <xref ref-type="bibr" rid="c14">Hashimoto et al., 2018</xref>; <xref ref-type="bibr" rid="c25">Kallies et al., 2020</xref>; <xref ref-type="bibr" rid="c35">McLane et al., 2019</xref>). Our results, together with studies published recently (<xref ref-type="bibr" rid="c2">Beltra et al., 2023</xref>; <xref ref-type="bibr" rid="c7">Codarri Deak et al., 2022</xref>; <xref ref-type="bibr" rid="c13">Hashimoto et al., 2022</xref>; <xref ref-type="bibr" rid="c29">Liu et al., 2021</xref>; <xref ref-type="bibr" rid="c39">Ren et al., 2022</xref>; <xref ref-type="bibr" rid="c44">Sun et al., 2023</xref>) suggest that regulating the T<sub>EX</sub> and T<sub>PEX</sub> cell balance is a central role of IL-2 and the downstream STAT5-BLIMP1 axis. Importantly, IL-2 promoted the generation of CX3CR1<sup>+</sup> effector-like T<sub>EX</sub> cells without compromising the self-renewal capacity of T<sub>PEX</sub> cells.</p>
<p>IL-2 signaling is mediated by both the high affinity receptor IL-2Rα (CD25) and the medium affinity receptor IL-2Rβ (CD122). Their individual contribution, however, is dependent on their respective expression levels as well as the dose of IL-2. We found that treatment with native IL-2 resulted in the upregulation of CD122 and induced feedforward signaling. Consistent with this observation, the IL-2 fusion protein ANV410 that selectively targets CD122 but not CD25 induced the generation of CX3CR1 effector-like T<sub>EX</sub> cells, overall suggesting that CD122 is the main mediator of IL-2 effects on T<sub>PEX</sub> cells. These results align well with recent studies, which showed that CD122-dependent signals drive terminal differentiation of CD8<sup>+</sup> T cells (<xref ref-type="bibr" rid="c3">Beltra et al., 2016</xref>) and CD122-biased IL-2 agonism in the combination with ICB promoted CD8<sup>+</sup> T cell effector function (<xref ref-type="bibr" rid="c7">Codarri Deak et al., 2022</xref>). Our results, however, do not preclude the possibility that IL-2 treatment can induce signaling through CD25 as reported (<xref ref-type="bibr" rid="c13">Hashimoto et al., 2022</xref>). Thus, IL-2 signaling is likely to be context-dependent. This notion is also highlighted by our data showing that early, in contrast to late, treatment with the IL-2 fusion protein ANV410 abrogated T<sub>PEX</sub> cell development and impaired the expansion of antigen-specific CD8<sup>+</sup> T cells.</p>
<p>Recent advancement in our understanding of the central role of IL-2 in the regulation of CD8<sup>+</sup> T cell expansion and function has reinvigorated the enthusiasm for IL-2-based immunotherapy in infection and cancer. Indeed, IL-2 and IL-2 fusion proteins have emerged as powerful modulators that may promote viral clearance or tumor control. Nevertheless, more work is required to understand the impact of IL-2 in a therapeutic setting on the function of T<sub>PEX</sub> cells and thus the long-term maintenance of CD8<sup>+</sup> T cell responses in chronic infection and in cancer. Furthermore, the facts that IL-2 signaling modulated the localization of CD8<sup>+</sup> T cells and altered the distribution of viral reservoirs which may have implications for people living with HIV or experiencing EBV active infection. Thus, further work is needed to dissect the therapeutic potential of IL-2. Taken together, the development of IL-2-based immunotherapies should not only target the correct receptor subunit but also consider T cell differentiation state and localization.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We acknowledge the Imaging and Cytometry Facility at the John Curtin School of Medical Research, The Australian National University and Flowcores at Monash University and Doherty Institute for technical support. We thank Shane P. Crotty (La Jolla Institute for Immunology) for STAT5b-CA and control vectors, William S Foster and James A. Harker (Imperial College London) for the advice on human studies. We thank ANAVEON for the supply of AN410.</p>
</ack>
<sec id="s4">
<title>Funding</title>
<p>Australian National Health and Medical Research Council (NHMRC) project GNT1085509 (DY), GNT2004333 (AK) and Leader Fellowship GNT2009554 (DY) National Natural Science Foundation of China (NSFC) project 82071792 (YW) Natural Science Foundation of Shandong Province 2021ZDSYS12 (YW) Swiss National Research Foundation fellowship (PMG)</p>
</sec>
<sec id="s5">
<title>Author Contributions</title>
<p>Conceptualization: DY and AK</p>
<p>Supervision: DY, AK and ZL</p>
<p>Data curation: YC, PZ, PMG, YAL, JH, YW, FVM, TZ, and JY</p>
<p>Formal analysis: PZ, YC, PMG, YAL, YW and MP</p>
<p>Funding acquisition: DY, AK, PMG and YW</p>
<p>Writing, review and editing: DY, AK, PZ, YC and PMG</p>
</sec>
<sec id="s6">
<title>Declaration of Interests</title>
<p>The authors declare no conflicts of interests.</p>
</sec>
<sec id="s7">
<title>Methods</title>
<sec id="s7a">
<title>Resource availability</title>
<sec id="s7a1">
<title>Lead contact</title>
<p>Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Di Yu (<email>di.yu@uq.edu.au</email>).</p>
</sec>
</sec>
<sec id="s7a2">
<title>Materials availability</title>
<p>This study did not generate new unique reagents.</p>
</sec>
<sec id="s7a3">
<title>Data and code availability</title>
<p>RNA-seq data were generated from datasets publicly available at GEO. Accession numbers are listed in the Key resources table. qPCR data, microscopy data, and any additional information required to reanalyse the data reported in this paper are available from the lead contact upon request. This paper does not report original code. Scripts and code utilised in this study are available from the lead contact upon request. Information regarding microglia isolation and sequencing can be addressed to Di Yu (<email>di.yu@uq.edu.au</email>).</p>
</sec>
<sec id="s8">
<title>Experimental model and study participant details</title>
<sec id="s8a">
<title>Mice</title>
<p>All mice used in this study were held in SPF (specific pathogen free) animal facilities in The Australian National University, Monash University, University of Melbourne or the Walter and Eliza Hall Institute (WEHI). 6-12 weeks C57BL/6 mice or <italic>Ptprca</italic> (CD45.1) mice were used for <italic>in vivo</italic> and <italic>in vitro</italic> experiments. P14 mice (JAX Tg(TcrLCMV)327Sdz) with the transgenic expression of a TCR specific for LCMV glycoprotein (GP)<sub>33-41</sub> were used for adoptive transfer experiment, and OT-I mice are with the transgenic expression of a TCR specific for chicken ovalbumin (OVA)<sub>257-264</sub>. <italic>Lck</italic><sup>Cre</sup> mice <italic>were crossed with Prdm1<sup>flox/flox</sup></italic> mice (<xref ref-type="bibr" rid="c24">Kallies et al., 2009</xref>). All animal experiment ethics were approved by the designated Animal Ethics Committee of the institutes that were responsible for animal experiments.</p>
</sec>
<sec id="s8b">
<title>Human data</title>
<p>The details of the prospective, open-label study of low-dose recombinant human IL-2 (rhIL-2) in patients with active SLE was described (<xref ref-type="bibr" rid="c15">He et al., 2016a</xref>). Briefly, three cycles of rhIL-2 were administered subcutaneously at a dose of 1 million IU every other day for 2 weeks (a total of 7 doses), followed by a 2-week break. Immunological data in peripheral blood mononuclear cells (PBMCs) were measured at baseline and every 2 weeks thereafter until week 12.</p>
</sec>
</sec>
<sec id="s9">
<title>Method details</title>
<sec id="s9a">
<title>Viral infection</title>
<p>Lymphocytic choriomeningitis virus (LCMV) Docile was propagated using BHK cell line which was cultured with complete DMEM medium. To study the role of IL-2 treatment in chronic LCMV infection, mice were intravenously (i.v.) infected with 1-2×10<sup>6</sup> PFU (plaque-forming units) of LCMV Docile virus in 100 ul of PBS.</p>
</sec>
<sec id="s9b">
<title>IL-2 and ANV410 treatment</title>
<p>10,000 to 100,000 I.U. (international units) of human rhIL-2 (recombinant human IL-2<sup>Ser125</sup>, Beijing SL Pharma) were intraperitoneally (i.p.) injected into the mice daily for 5 times from days 10 to 14 post LCMV Docile infection. Mice were sacrificed on day 15 post infection and samples were collected for further examination. ANV410, supplied by Anaveon AG (Basel, Switzerland), is a human IL-2/anti-IL-2 circularly permutated fusion protein which selectively signals through the intermediate affinity IL-2R (IL-2Rβ/γ). For treatment with ANV410, naïve or Docile infected mice were treated with 200 μg/kg body weight three times (every other day in five days).</p>
</sec>
<sec id="s9c">
<title>Generation of bone marrow chimeric mice</title>
<p>Bone marrow (BM) cells were collected from femurs of 6-12 weeks old mice with indicated genotypes. Single cells were prepared by pipetting in complete RPMI media. CD45.1 recipient mouse were lethally irradiated twice with 4.75 gray (Gy) of gamma radiation 4 hours apart. BLIMP1-deficient BM cells (CD45.2) were mixed with wildtype control BM cells (CD45.1/CD45.2) at 1:1 ratio and intravenously transferred into irradiated CD45.1 recipient mouse. As control, BM cells from genotyped wild type littermates (CD45.2) were also mixed with wildtype control BM (CD45.1/CD45.2) and reconstituted in recipient CD45.1 mice. Mice were housed for 6 to 8 weeks to allow hematopoietic reconstitution before infection with LCMV Docile virus.</p>
</sec>
<sec id="s9d">
<title><italic>In vitro</italic> induction of CXCR5<sup>+</sup> CD8<sup>+</sup> cells</title>
<p>For induction of CXCR5<sup>+</sup> CD8<sup>+</sup> T cells, naïve OT-I cells (CD8<sup>+</sup>Va2<sup>+</sup>CD44<sup>-</sup>CD62L<sup>+</sup>) were purified (10<sup>4</sup> cells/well) and co-cultured with congenical wildtype splenocytes (10<sup>5</sup> cells/well) in 96-well plates, in the presence of the SINFEKL peptide (1 µM) with indicated cytokines: TGFβ (10 ng/mL), IL-6 (100 ng/mL) and IL-2 (500 I.U./mL∼30-50ng/mL).</p>
</sec>
<sec id="s9e">
<title>Retroviral transduction on primary cells</title>
<p>GFP bicistronic retroviral vector containing STAT5b-CA or empty vector as described (<xref ref-type="bibr" rid="c22">Johnston et al., 2012</xref>) were used to study the overexpression of STAT5b-CA in primary mouse CD8<sup>+</sup> T cells. Retroviruses were generated by transfecting the plasmids into a retrovirus-packaging cell line GPE86 using lipofectamine 2000 reagent (Invitrogen). GFP positive GPE86 were cell sorted to isolate stably transfected cells. Stably transfected GPE86 were then cultured in complete DMEM media for 48 hours before the culture supernatant were collected for the transduction of primary cells. Naïve P14 T cells were purified from CD45.2 TCR transgenic P14 mice and stimulated with plate bound anti-CD3 and anti-CD28 for 48 hours. Activated P14 T cells were spinoculated at 800g for 1 hour at 32°C with the retrovirus supernatants packaged by GPE86 cells. Transduced P14 T cells were rested in fresh cRPMI media containing 20 ng/mL of rmIL-7 for 48 hours. About 6,000 GFP<sup>+</sup> P14 T cells were sorted by flow cytometry and intravenously (i.v.) transferred into CD45.1 recipient mouse. One day after adoptive transfer, mice were i.v. infected with LCMV Docile at 10<sup>6</sup> PFU. Mice were culled on day 8 post infection for analyses.</p>
</sec>
<sec id="s9f">
<title>Flow cytometry</title>
<p>Single cells were washed, counted, and stained with Fc-receptor blocking antibodies (clone 2.4G2, 1:100 dilution, BD) for 10 min on ice to block non-specific staining. For surface staining, cells were washed once with PBS containing 2% heat-inactivated fetal bovine serum (FBS, Gibco) and stained in an appropriately diluted antibody solution for at least 30 min at 4 °C. The 7-amino-actinomycin D (7-AAD) (BioLegend) was stained to exclude dead cells. For intracellular staining, Cytofix/Cytoperm (BD) was used as user’s guide. For intranuclear staining, Foxp3/Transcription Factor Staining Buffer Set (eBioscience) was used as user’s guide. To detect LCMV antigen-specific CD8<sup>+</sup> T cells, APC-conjugated H-2D<sup>b</sup>-GP<sub>33</sub>-tetramer (produced by Biomolecular Resource Facility at The John Curtin School of Medical Research, The Australian National University). To detect LCMV-infected T cells, purified anti-LCMV nucleoprotein (clone VL4) antibody was labelled with Alexa Fluor (AF) 647 using antibody labelling kit (Invitrogen). Splenocytes from LCMV infected mice were first stained with surface antibodies. After permeabilization by the Cytofix/Cytoperm (BD) kit, labelled AF647-VL4 antibody was incubated with the cells for 30 min at 25 °C. Uninfected splenocytes and VL4 unstained splenocytes were used as negative control. Data were collected on a LSR-II or LSRFortessaTM (BD) and analyzed using FlowJo software.</p>
</sec>
<sec id="s9g">
<title>Immunofluorescence</title>
<p>To visualize LCMV infection and P14 cells in splenic tissues, immunofluorescent staining was performed. The middle section of spleens was cut and submerged immediately in Optimal Cutting Temperature (OCT) compound on dry ice and stored at –80°C. OCT blocks were then sectioned at 5 to 10 μm thickness at –20°C. Sections were blocked with Fc-receptor-blocking antibody (clone 2.4G2, 1:100, BD), followed by staining with primary antibodies. Then sections were washed and stained with secondary antibodies or streptavidin. All steps were performed at 25 °C for 60 min in dark and sections were mounted using Prolong Gold (Invitrogen). Slides were visualized using laser scanning confocal microscopy (Leica SP5) at the John Curtin School of Medical Research. Quantification of infected cells was performed by automatic counting of cells per area of section using Imaris 9.0 software.</p>
</sec>
<sec id="s9h">
<title>RNA sequencing and bioinformatics analysis</title>
<p>RNA sequencing and bioinformatic analyses to compare the transcriptomes between CXCR5<sup>−</sup> and CXCR5<sup>+</sup> P14 cells were described previously (<xref ref-type="bibr" rid="c28">Leong et al., 2016</xref>). DESeq2 from Bioconductor software (<xref ref-type="bibr" rid="c30">Love et al., 2014</xref>) was used to normalize gene counts in GSE76279 dataset, and the genes were ranked based on –log(adjusted p-value of fold change). The ranked list was introduced to GSEA software (<xref ref-type="bibr" rid="c43">Subramanian et al., 2005</xref>) to enrich genes in gene sets of a wide range of databases using a curated version of “msigdb v7.2 symbols”. The normalized counts were also filtered for interleukin receptors to produce a heatmap using pheatmap function in r and to construct a bar chart in GraphPad Prism 9. Multiple unpaired t-tests were used to show the level of significancy.</p>
</sec>
</sec>
<sec id="s10">
<title>Quantification and statistical analysis</title>
<sec id="s10a">
<title>Statistical analysis</title>
<p>All results were analyzed by unpaired or paired and two-tailed student t-test for comparison between two groups or one-way ANOVA for calculating univariate data set with more than two groups by GraphPad Prism 8.0 software, unless otherwise specified. Differences were considered to be statistically significant at p &lt; 0.05.</p>
</sec>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alfei</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Kanev</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Hofmann</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Ghoneim</surname>, <given-names>H.E.</given-names></string-name>, <string-name><surname>Roelli</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Utzschneider</surname>, <given-names>D.T.</given-names></string-name>, <string-name><surname>von Hoesslin</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Cullen</surname>, <given-names>J.G.</given-names></string-name>, <string-name><surname>Fan</surname>, <given-names>Y.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2019</year>). <article-title>TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection</article-title>. <source>Nature</source> <volume>571</volume>, <fpage>265</fpage>–<lpage>269</lpage>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beltra</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Abdel-Hakeem</surname>, <given-names>M.S.</given-names></string-name>, <string-name><surname>Manne</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Huang</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Kurachi</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Su</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Picton</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Ngiow</surname>, <given-names>S.F.</given-names></string-name>, <string-name><surname>Muroyama</surname>, <given-names>Y.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2023</year>). <article-title>Stat5 opposes the transcription factor Tox and rewires exhausted CD8(+) T cells toward durable effector-like states during chronic antigen exposure</article-title>. <source>Immunity</source> <volume>56</volume>, <fpage>2699</fpage>–<lpage>2718.</lpage> </mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beltra</surname>, <given-names>J.C.</given-names></string-name>, <string-name><surname>Bourbonnais</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Bedard</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Charpentier</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Boulange</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Michaud</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Boufaied</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Bruneau</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Shoukry</surname>, <given-names>N.H.</given-names></string-name>, <string-name><surname>Lamarre</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>IL2Rbeta-dependent signals drive terminal exhaustion and suppress memory development during chronic viral infection</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>113</volume>, <fpage>E5444</fpage>–<lpage>5453</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blank</surname>, <given-names>C.U.</given-names></string-name>, <string-name><surname>Haining</surname>, <given-names>W.N.</given-names></string-name>, <string-name><surname>Held</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Hogan</surname>, <given-names>P.G.</given-names></string-name>, <string-name><surname>Kallies</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Lugli</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Lynn</surname>, <given-names>R.C.</given-names></string-name>, <string-name><surname>Philip</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Rao</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Restifo</surname>, <given-names>N.P.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2019</year>). <article-title>Defining ‘T cell exhaustion’</article-title>. <source>Nat Rev Immunol</source> <volume>19</volume>, <fpage>665</fpage>–<lpage>674</lpage>.</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Blattman</surname>, <given-names>J.N.</given-names></string-name>, <string-name><surname>Grayson</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Wherry</surname>, <given-names>E.J.</given-names></string-name>, <string-name><surname>Kaech</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>K.A.</given-names></string-name>, and <string-name><surname>Ahmed</surname>, <given-names>R</given-names></string-name></person-group>. (<year>2003</year>). <article-title>Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo</article-title>. <source>Nat Med</source> <volume>9</volume>, <fpage>540</fpage>–<lpage>547</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boyman</surname>, <given-names>O.</given-names></string-name>, and <string-name><surname>Sprent</surname>, <given-names>J</given-names></string-name></person-group>. (<year>2012</year>). <article-title>The role of interleukin-2 during homeostasis and activation of the immune system</article-title>. <source>Nat Rev Immunol</source> <volume>12</volume>, <fpage>180</fpage>–<lpage>190</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Codarri Deak</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Nicolini</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Hashimoto</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Karagianni</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Schwalie</surname>, <given-names>P.C.</given-names></string-name>, <string-name><surname>Lauener</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Varypataki</surname>, <given-names>E.M.</given-names></string-name>, <string-name><surname>Richard</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Bommer</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Sam</surname>, <given-names>J.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2022</year>). <article-title>PD-1-cis IL-2R agonism yields better effectors from stem-like CD8(+) T cells</article-title>. <source>Nature</source> <volume>610</volume>, <fpage>161</fpage>–<lpage>172</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Collins</surname>, <given-names>D.R.</given-names></string-name>, <string-name><surname>Hitschfel</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Urbach</surname>, <given-names>J.M.</given-names></string-name>, <string-name><surname>Mylvaganam</surname>, <given-names>G.H.</given-names></string-name>, <string-name><surname>Ly</surname>, <given-names>N.L.</given-names></string-name>, <string-name><surname>Arshad</surname>, <given-names>U.</given-names></string-name>, <string-name><surname>Racenet</surname>, <given-names>Z.J.</given-names></string-name>, <string-name><surname>Yanez</surname>, <given-names>A.G.</given-names></string-name>, <string-name><surname>Diefenbach</surname>, <given-names>T.J.</given-names></string-name>, and <string-name><surname>Walker</surname>, <given-names>B.D.</given-names></string-name></person-group> (<year>2023</year>). <article-title>Cytolytic CD8(+) T cells infiltrate germinal centers to limit ongoing HIV replication in spontaneous controller lymph nodes</article-title>. <source>Sci Immunol</source> <volume>8</volume>, <fpage>eade5872</fpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dutcher</surname>, <given-names>J.P.</given-names></string-name>, <string-name><surname>Schwartzentruber</surname>, <given-names>D.J.</given-names></string-name>, <string-name><surname>Kaufman</surname>, <given-names>H.L.</given-names></string-name>, <string-name><surname>Agarwala</surname>, <given-names>S.S.</given-names></string-name>, <string-name><surname>Tarhini</surname>, <given-names>A.A.</given-names></string-name>, <string-name><surname>Lowder</surname>, <given-names>J.N.</given-names></string-name>, and <string-name><surname>Atkins</surname>, <given-names>M.B</given-names></string-name></person-group>. (<year>2014</year>). <article-title>High dose interleukin-2 (Aldesleukin) – expert consensus on best management practices-2014</article-title>. <source>J Immunother Cancer</source> <volume>2</volume>, <fpage>26</fpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Eberhardt</surname>, <given-names>C.S.</given-names></string-name>, <string-name><surname>Kissick</surname>, <given-names>H.T.</given-names></string-name>, <string-name><surname>Patel</surname>, <given-names>M.R.</given-names></string-name>, <string-name><surname>Cardenas</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Prokhnevska</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Obeng</surname>, <given-names>R.C.</given-names></string-name>, <string-name><surname>Nasti</surname>, <given-names>T.H.</given-names></string-name>, <string-name><surname>Griffith</surname>, <given-names>C.C.</given-names></string-name>, <string-name><surname>Im</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>X.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2021</year>). <article-title>Functional HPV-specific PD-1(+) stem-like CD8 T cells in head and neck cancer</article-title>. <source>Nature</source> <volume>597</volume>, <fpage>279</fpage>–<lpage>284</lpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gabriel</surname>, <given-names>S.S.</given-names></string-name>, <string-name><surname>Tsui</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Chisanga</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Weber</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Llano-Leon</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Gubser</surname>, <given-names>P.M.</given-names></string-name>, <string-name><surname>Bartholin</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Souza-Fonseca-Guimaraes</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Huntington</surname>, <given-names>N.D.</given-names></string-name>, <string-name><surname>Shi</surname>, <given-names>W.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2021</year>). <article-title>Transforming growth factor-beta-regulated mTOR activity preserves cellular metabolism to maintain long-term T cell responses in chronic infection</article-title>. <source>Immunity</source> <volume>54</volume>, <fpage>1698</fpage>–<lpage>1714.</lpage> </mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gautam</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Fioravanti</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zhu</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Le Gall</surname>, <given-names>J.B.</given-names></string-name>, <string-name><surname>Brohawn</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Lacey</surname>, <given-names>N.E.</given-names></string-name>, <string-name><surname>Hu</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Hocker</surname>, <given-names>J.D.</given-names></string-name>, <string-name><surname>Hawk</surname>, <given-names>N.V.</given-names></string-name>, <string-name><surname>Kapoor</surname>, <given-names>V.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2019</year>). <article-title>The transcription factor c-Myb regulates CD8(+) T cell stemness and antitumor immunity</article-title>. <source>Nat Immunol</source> <volume>20</volume>, <fpage>337</fpage>–<lpage>349</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hashimoto</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Araki</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Cardenas</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Jadhav</surname>, <given-names>R.R.</given-names></string-name>, <string-name><surname>Kissick</surname>, <given-names>H.T.</given-names></string-name>, <string-name><surname>Hudson</surname>, <given-names>W.H.</given-names></string-name>, <string-name><surname>McGuire</surname>, <given-names>D.J.</given-names></string-name>, <string-name><surname>Obeng</surname>, <given-names>R.C.</given-names></string-name>, <string-name><surname>Wieland</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2022</year>). <article-title>PD-1 combination therapy with IL-2 modifies CD8(+) T cell exhaustion program</article-title>. <source>Nature</source> <volume>610</volume>, <fpage>173</fpage>–<lpage>181</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hashimoto</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kamphorst</surname>, <given-names>A.O.</given-names></string-name>, <string-name><surname>Im</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Kissick</surname>, <given-names>H.T.</given-names></string-name>, <string-name><surname>Pillai</surname>, <given-names>R.N.</given-names></string-name>, <string-name><surname>Ramalingam</surname>, <given-names>S.S.</given-names></string-name>, <string-name><surname>Araki</surname>, <given-names>K.</given-names></string-name>, and <string-name><surname>Ahmed</surname>, <given-names>R</given-names></string-name></person-group>. (<year>2018</year>). <article-title>CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions</article-title>. <source>Annu Rev Med</source> <volume>69</volume>, <fpage>301</fpage>–<lpage>318</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Wei</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Deng</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Jin</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Gan</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Hu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Jia</surname>, <given-names>R.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016a</year>). <article-title>Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus</article-title>. <source>Nat Med</source> <volume>22</volume>, <fpage>991</fpage>–<lpage>993</lpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Hou</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Bai</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Han</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Wei</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Shen</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>X.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016b</year>). <article-title>Follicular CXCR5-expressing CD8(+) T cells curtail chronic viral infection</article-title>. <source>Nature</source> <volume>537</volume>, <fpage>412</fpage>–<lpage>428</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Hudson</surname>, <given-names>W.H.</given-names></string-name>, <string-name><surname>Kissick</surname>, <given-names>H.T.</given-names></string-name>, <string-name><surname>Medina</surname>, <given-names>C.B.</given-names></string-name>, <string-name><surname>Baptista</surname>, <given-names>A.P.</given-names></string-name>, <string-name><surname>Ma</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Liao</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Germain</surname>, <given-names>R.N.</given-names></string-name>, <string-name><surname>Turley</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>N.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2022</year>). <article-title>TGF-beta regulates the stem-like state of PD-1+ TCF-1+ virus-specific CD8 T cells during chronic infection</article-title>. <source>J Exp Med</source> <volume>219</volume>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Lu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Xiong</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Tian</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Lin</surname>, <given-names>H.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2022</year>). <article-title>The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes</article-title>. <source>Cell</source> <volume>185</volume>, <fpage>4049</fpage>–<lpage>4066.</lpage> </mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hudson</surname>, <given-names>W.H.</given-names></string-name>, <string-name><surname>Gensheimer</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Hashimoto</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Wieland</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Valanparambil</surname>, <given-names>R.M.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Lin</surname>, <given-names>J.X.</given-names></string-name>, <string-name><surname>Konieczny</surname>, <given-names>B.T.</given-names></string-name>, <string-name><surname>Im</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Freeman</surname>, <given-names>G.J.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2019</year>). <article-title>Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1(+) Stem-like CD8(+) T Cells during Chronic Infection</article-title>. <source>Immunity</source> <volume>51</volume>, <fpage>1043</fpage>–<lpage>1058.</lpage> </mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Humblet-Baron</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Franckaert</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Dooley</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Bornschein</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Cauwe</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Schonefeldt</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Bossuyt</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Matthys</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Baron</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Wouters</surname>, <given-names>C.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis</article-title>. <source>J Allergy Clin Immunol</source> <volume>138</volume>, <fpage>200</fpage>–<lpage>209.</lpage> </mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Im</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Hashimoto</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Gerner</surname>, <given-names>M.Y.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Kissick</surname>, <given-names>H.T.</given-names></string-name>, <string-name><surname>Burger</surname>, <given-names>M.C.</given-names></string-name>, <string-name><surname>Shan</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Hale</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Lee</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Nasti</surname>, <given-names>T.H.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy</article-title>. <source>Nature</source> <volume>537</volume>, <fpage>417</fpage>–<lpage>421</lpage>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnston</surname>, <given-names>R.J.</given-names></string-name>, <string-name><surname>Choi</surname>, <given-names>Y.S.</given-names></string-name>, <string-name><surname>Diamond</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Yang</surname>, <given-names>J.A.</given-names></string-name>, and <string-name><surname>Crotty</surname>, <given-names>S</given-names></string-name></person-group>. (<year>2012</year>). <article-title>STAT5 is a potent negative regulator of TFH cell differentiation</article-title>. <source>J Exp Med</source> <volume>209</volume>, <fpage>243</fpage>–<lpage>250</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnston</surname>, <given-names>R.J.</given-names></string-name>, <string-name><surname>Poholek</surname>, <given-names>A.C.</given-names></string-name>, <string-name><surname>DiToro</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Yusuf</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Eto</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Barnett</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Dent</surname>, <given-names>A.L.</given-names></string-name>, <string-name><surname>Craft</surname>, <given-names>J.</given-names></string-name>, and <string-name><surname>Crotty</surname>, <given-names>S</given-names></string-name></person-group>. (<year>2009</year>). <article-title>Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation</article-title>. <source>Science</source> <volume>325</volume>, <fpage>1006</fpage>–<lpage>1010</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kallies</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Xin</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Belz</surname>, <given-names>G.T.</given-names></string-name>, and <string-name><surname>Nutt</surname>, <given-names>S.L</given-names></string-name></person-group>. (<year>2009</year>). <article-title>Blimp-1 transcription factor is required for the differentiation of effector CD8+ T cells and memory responses</article-title>. <source>Immunity</source> <volume>31</volume>, <fpage>283</fpage>–<lpage>295</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kallies</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Zehn</surname>, <given-names>D.</given-names></string-name>, and <string-name><surname>Utzschneider</surname>, <given-names>D.T</given-names></string-name></person-group>. (<year>2020</year>). <article-title>Precursor exhausted T cells: key to successful immunotherapy?</article-title> <source>Nat Rev Immunol</source> <volume>20</volume>, <fpage>128</fpage>–<lpage>136</lpage>.</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khan</surname>, <given-names>O.</given-names></string-name>, <string-name><surname>Giles</surname>, <given-names>J.R.</given-names></string-name>, <string-name><surname>McDonald</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Manne</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ngiow</surname>, <given-names>S.F.</given-names></string-name>, <string-name><surname>Patel</surname>, <given-names>K.P.</given-names></string-name>, <string-name><surname>Werner</surname>, <given-names>M.T.</given-names></string-name>, <string-name><surname>Huang</surname>, <given-names>A.C.</given-names></string-name>, <string-name><surname>Alexander</surname>, <given-names>K.A.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>J.E.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2019</year>). <article-title>TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion</article-title>. <source>Nature</source> <volume>571</volume>, <fpage>211</fpage>–<lpage>218</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kunz</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Sevilla</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>McGavern</surname>, <given-names>D.B.</given-names></string-name>, <string-name><surname>Campbell</surname>, <given-names>K.P.</given-names></string-name>, and <string-name><surname>Oldstone</surname>, <given-names>M.B</given-names></string-name></person-group>. (<year>2001</year>). <article-title>Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan</article-title>. <source>J Cell Biol</source> <volume>155</volume>, <fpage>301</fpage>–<lpage>310</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Leong</surname>, <given-names>Y.A.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Ong</surname>, <given-names>H.S.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Man</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Deleage</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Minnich</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Meckiff</surname>, <given-names>B.J.</given-names></string-name>, <string-name><surname>Wei</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Hou</surname>, <given-names>Z.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles</article-title>. <source>Nat Immunol</source> <volume>17</volume>, <fpage>1187</fpage>–<lpage>1196</lpage>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zhou</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Fang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Deng</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Gao</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Liang</surname>, <given-names>X.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2021</year>). <article-title>IL-2 regulates tumor-reactive CD8(+) T cell exhaustion by activating the aryl hydrocarbon receptor</article-title>. <source>Nat Immunol</source> <volume>22</volume>, <fpage>358</fpage>–<lpage>369</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Love</surname>, <given-names>M.I.</given-names></string-name>, <string-name><surname>Huber</surname>, <given-names>W.</given-names></string-name>, and <string-name><surname>Anders</surname>, <given-names>S</given-names></string-name></person-group>. (<year>2014</year>). <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol</source> <volume>15</volume>, <fpage>550</fpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ma</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Liao</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Mishra</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Qiu</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Lu</surname>, <given-names>Q.</given-names></string-name>, and <string-name><surname>Zhang</surname>, <given-names>N</given-names></string-name></person-group>. (<year>2022</year>). <article-title>TGF-beta promotes stem-like T cells via enforcing their lymphoid tissue retention</article-title>. <source>J Exp Med</source> <volume>219</volume>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Man</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Gabriel</surname>, <given-names>S.S.</given-names></string-name>, <string-name><surname>Liao</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Gloury</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Preston</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Henstridge</surname>, <given-names>D.C.</given-names></string-name>, <string-name><surname>Pellegrini</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Zehn</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Berberich-Siebelt</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Febbraio</surname>, <given-names>M.A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2017</year>). <article-title>Transcription Factor IRF4 Promotes CD8(+) T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection</article-title>. <source>Immunity</source> <volume>47</volume>, <fpage>1129</fpage>–<lpage>1141.</lpage> </mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Martinez</surname>, <given-names>G.J.</given-names></string-name>, <string-name><surname>Pereira</surname>, <given-names>R.M.</given-names></string-name>, <string-name><surname>Aijo</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Kim</surname>, <given-names>E.Y.</given-names></string-name>, <string-name><surname>Marangoni</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Pipkin</surname>, <given-names>M.E.</given-names></string-name>, <string-name><surname>Togher</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Heissmeyer</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>Y.C.</given-names></string-name>, <string-name><surname>Crotty</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2015</year>). <article-title>The transcription factor NFAT promotes exhaustion of activated CD8(+) T cells</article-title>. <source>Immunity</source> <volume>42</volume>, <fpage>265</fpage>–<lpage>278</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marx</surname>, <given-names>A.F.</given-names></string-name>, <string-name><surname>Kallert</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Brunner</surname>, <given-names>T.M.</given-names></string-name>, <string-name><surname>Villegas</surname>, <given-names>J.A.</given-names></string-name>, <string-name><surname>Geier</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Fixemer</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Abreu-Mota</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Reuther</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Bonilla</surname>, <given-names>W.V.</given-names></string-name>, <string-name><surname>Fadejeva</surname>, <given-names>J.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2023</year>). <article-title>The alarmin interleukin-33 promotes the expansion and preserves the stemness of Tcf-1(+) CD8(+) T cells in chronic viral infection</article-title>. <source>Immunity</source> <volume>56</volume>, <fpage>813</fpage>–<lpage>828.</lpage> </mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McLane</surname>, <given-names>L.M.</given-names></string-name>, <string-name><surname>Abdel-Hakeem</surname>, <given-names>M.S.</given-names></string-name>, and <string-name><surname>Wherry</surname>, <given-names>E.J</given-names></string-name></person-group>. (<year>2019</year>). <article-title>CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer</article-title>. <source>Annu Rev Immunol</source> <volume>37</volume>, <fpage>457</fpage>–<lpage>495</lpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mylvaganam</surname>, <given-names>G.H.</given-names></string-name>, <string-name><surname>Rios</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Abdelaal</surname>, <given-names>H.M.</given-names></string-name>, <string-name><surname>Iyer</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Tharp</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Mavigner</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Hicks</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Chahroudi</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Ahmed</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Bosinger</surname>, <given-names>S.E.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2017</year>). <article-title>Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>114</volume>, <fpage>1976</fpage>–<lpage>1981</lpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oldstone</surname>, <given-names>M.B.</given-names></string-name>, and <string-name><surname>Campbell</surname>, <given-names>K.P</given-names></string-name></person-group>. (<year>2011</year>). <article-title>Decoding arenavirus pathogenesis: essential roles for alpha-dystroglycan-virus interactions and the immune response</article-title>. <source>Virology</source> <volume>411</volume>, <fpage>170</fpage>–<lpage>179</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Petrovas</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Ferrando-Martinez</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Gerner</surname>, <given-names>M.Y.</given-names></string-name>, <string-name><surname>Casazza</surname>, <given-names>J.P.</given-names></string-name>, <string-name><surname>Pegu</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Deleage</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Cooper</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Hataye</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Andrews</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ambrozak</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2017</year>). <article-title>Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies</article-title>. <source>Sci Transl Med</source> <volume>9</volume>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ren</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Liang</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Ye</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Qiao</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>B.</given-names></string-name>, and <string-name><surname>Fu</surname>, <given-names>Y.X</given-names></string-name></person-group>. (<year>2022</year>). <article-title>Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity</article-title>. <source>J Clin Invest</source> <volume>132</volume>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scott</surname>, <given-names>A.C.</given-names></string-name>, <string-name><surname>Dundar</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Zumbo</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Chandran</surname>, <given-names>S.S.</given-names></string-name>, <string-name><surname>Klebanoff</surname>, <given-names>C.A.</given-names></string-name>, <string-name><surname>Shakiba</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Trivedi</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Menocal</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Appleby</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Camara</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2019</year>). <article-title>TOX is a critical regulator of tumour-specific T cell differentiation</article-title>. <source>Nature</source> <volume>571</volume>, <fpage>270</fpage>–<lpage>274</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seo</surname>, <given-names>H.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Gonzalez-Avalos</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Samaniego-Castruita</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Das</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Wang</surname>, <given-names>Y.H.</given-names></string-name>, <string-name><surname>Lopez-Moyado</surname>, <given-names>I.F.</given-names></string-name>, <string-name><surname>Georges</surname>, <given-names>R.O.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Onodera</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2019</year>). <article-title>TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>116</volume>, <fpage>12410</fpage>–<lpage>12415</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siddiqui</surname>, <given-names>I.</given-names></string-name>, <string-name><surname>Schaeuble</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Chennupati</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Fuertes Marraco</surname>, <given-names>S.A.</given-names></string-name>, <string-name><surname>Calderon-Copete</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Pais Ferreira</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Carmona</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Scarpellino</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Gfeller</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Pradervand</surname>, <given-names>S.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2019</year>). <article-title>Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy</article-title>. <source>Immunity</source> <volume>50</volume>, <fpage>195</fpage>–<lpage>211.</lpage> </mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Subramanian</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Tamayo</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Mootha</surname>, <given-names>V.K.</given-names></string-name>, <string-name><surname>Mukherjee</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Ebert</surname>, <given-names>B.L.</given-names></string-name>, <string-name><surname>Gillette</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Paulovich</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Pomeroy</surname>, <given-names>S.L.</given-names></string-name>, <string-name><surname>Golub</surname>, <given-names>T.R.</given-names></string-name>, <string-name><surname>Lander</surname>, <given-names>E.S.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2005</year>). <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc Natl Acad Sci U S A</source> <volume>102</volume>, <fpage>15545</fpage>–<lpage>15550</lpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname>, <given-names>Q.</given-names></string-name>, <string-name><surname>Cai</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Zhao</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>W.</given-names></string-name>, <string-name><surname>Xie</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Gou</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Wei</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2023</year>). <article-title>BCL6 promotes a stem-like CD8(+) T cell program in cancer via antagonizing BLIMP1</article-title>. <source>Sci Immunol</source> <volume>8</volume>, <fpage>eadh1306</fpage>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tichet</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Wullschleger</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Chryplewicz</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Fournier</surname>, <given-names>N.</given-names></string-name>, <string-name><surname>Marcone</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Kauzlaric</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Homicsko</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Deak</surname>, <given-names>L.C.</given-names></string-name>, <string-name><surname>Umana</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Klein</surname>, <given-names>C.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2023</year>). <article-title>Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8(+) T cells and reprogramming macrophages</article-title>. <source>Immunity</source> <volume>56</volume>, <fpage>162</fpage>–<lpage>179.</lpage> </mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tsui</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Kretschmer</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Rapelius</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Gabriel</surname>, <given-names>S.S.</given-names></string-name>, <string-name><surname>Chisanga</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Knopper</surname>, <given-names>K.</given-names></string-name>, <string-name><surname>Utzschneider</surname>, <given-names>D.T.</given-names></string-name>, <string-name><surname>Nussing</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Liao</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Mason</surname>, <given-names>T.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2022</year>). <article-title>MYB orchestrates T cell exhaustion and response to checkpoint inhibition</article-title>. <source>Nature</source> <volume>609</volume>, <fpage>354</fpage>–<lpage>360</lpage>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Utzschneider</surname>, <given-names>D.T.</given-names></string-name>, <string-name><surname>Charmoy</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Chennupati</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Pousse</surname>, <given-names>L.</given-names></string-name>, <string-name><surname>Ferreira</surname>, <given-names>D.P.</given-names></string-name>, <string-name><surname>Calderon-Copete</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Danilo</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Alfei</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Hofmann</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Wieland</surname>, <given-names>D.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections</article-title>. <source>Immunity</source> <volume>45</volume>, <fpage>415</fpage>–<lpage>427</lpage>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vinuesa</surname>, <given-names>C.G.</given-names></string-name>, <string-name><surname>Linterman</surname>, <given-names>M.A.</given-names></string-name>, <string-name><surname>Yu</surname>, <given-names>D.</given-names></string-name>, and <string-name><surname>MacLennan</surname>, <given-names>I.C</given-names></string-name></person-group>. (<year>2016</year>). <article-title>Follicular Helper T Cells</article-title>. <source>Annu Rev Immunol</source> <volume>34</volume>, <fpage>335</fpage>–<lpage>368</lpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>West</surname>, <given-names>E.E.</given-names></string-name>, <string-name><surname>Jin</surname>, <given-names>H.T.</given-names></string-name>, <string-name><surname>Rasheed</surname>, <given-names>A.U.</given-names></string-name>, <string-name><surname>Penaloza-Macmaster</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Ha</surname>, <given-names>S.J.</given-names></string-name>, <string-name><surname>Tan</surname>, <given-names>W.G.</given-names></string-name>, <string-name><surname>Youngblood</surname>, <given-names>B.</given-names></string-name>, <string-name><surname>Freeman</surname>, <given-names>G.J.</given-names></string-name>, <string-name><surname>Smith</surname>, <given-names>K.A.</given-names></string-name>, and <string-name><surname>Ahmed</surname>, <given-names>R</given-names></string-name></person-group>. (<year>2013</year>). <article-title>PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells</article-title>. <source>J Clin Invest</source> <volume>123</volume>, <fpage>2604</fpage>–<lpage>2615</lpage>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Ji</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Moseman</surname>, <given-names>E.A.</given-names></string-name>, <string-name><surname>Xu</surname>, <given-names>H.C.</given-names></string-name>, <string-name><surname>Manglani</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Kirby</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Anderson</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Handon</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Kenyon</surname>, <given-names>E.</given-names></string-name>, <string-name><surname>Elkahloun</surname>, <given-names>A.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness</article-title>. <source>Sci Immunol</source> <fpage>1</fpage>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xin</surname>, <given-names>A.</given-names></string-name>, <string-name><surname>Masson</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Liao</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Preston</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Guan</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Gloury</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Olshansky</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Lin</surname>, <given-names>J.X.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Speed</surname>, <given-names>T.P.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2016</year>). <article-title>A molecular threshold for effector CD8(+) T cell differentiation controlled by transcription factors Blimp-1 and T-bet</article-title>. <source>Nat Immunol</source> <volume>17</volume>, <fpage>422</fpage>–<lpage>432</lpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yan</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Cao</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Harrington</surname>, <given-names>S.M.</given-names></string-name>, <string-name><surname>Bindeman</surname>, <given-names>W.E.</given-names></string-name>, <string-name><surname>Adjei</surname>, <given-names>A.A.</given-names></string-name>, <string-name><surname>Jang</surname>, <given-names>J.S.</given-names></string-name>, <string-name><surname>Jen</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Li</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Chanana</surname>, <given-names>P.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2018</year>). <article-title>CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy</article-title>. <source>JCI Insight</source> <volume>3</volume>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yao</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Sun</surname>, <given-names>H.W.</given-names></string-name>, <string-name><surname>Lacey</surname>, <given-names>N.E.</given-names></string-name>, <string-name><surname>Ji</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Moseman</surname>, <given-names>E.A.</given-names></string-name>, <string-name><surname>Shih</surname>, <given-names>H.Y.</given-names></string-name>, <string-name><surname>Heuston</surname>, <given-names>E.F.</given-names></string-name>, <string-name><surname>Kirby</surname>, <given-names>M.</given-names></string-name>, <string-name><surname>Anderson</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Cheng</surname>, <given-names>J.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2019</year>). <article-title>Single-cell RNA-seq reveals TOX as a key regulator of CD8(+) T cell persistence in chronic infection</article-title>. <source>Nat Immunol</source> <volume>20</volume>, <fpage>890</fpage>–<lpage>901</lpage>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Walker</surname>, <given-names>L.S.K.</given-names></string-name>, <string-name><surname>Liu</surname>, <given-names>Z.</given-names></string-name>, <string-name><surname>Linterman</surname>, <given-names>M.A.</given-names></string-name>, and <string-name><surname>Li</surname>, <given-names>Z</given-names></string-name></person-group>. (<year>2022</year>). <article-title>Targeting T(FH) cells in human diseases and vaccination: rationale and practice</article-title>. <source>Nat Immunol</source> <volume>23</volume>, <fpage>1157</fpage>–<lpage>1168</lpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname>, <given-names>D.</given-names></string-name>, and <string-name><surname>Ye</surname>, <given-names>L</given-names></string-name></person-group>. (<year>2018</year>). <article-title>A Portrait of CXCR5(+) Follicular Cytotoxic CD8(+) T cells</article-title>. <source>Trends Immunol</source> <volume>39</volume>, <fpage>965</fpage>–<lpage>979</lpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zander</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Kasmani</surname>, <given-names>M.Y.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>Y.</given-names></string-name>, <string-name><surname>Topchyan</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Shen</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>S.</given-names></string-name>, <string-name><surname>Burns</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Ingram</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Cui</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Joshi</surname>, <given-names>N.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2022</year>). <article-title>Tfh-cell-derived interleukin 21 sustains effector CD8(+) T cell responses during chronic viral infection</article-title>. <source>Immunity</source> <volume>55</volume>, <fpage>475</fpage>–<lpage>493.</lpage> </mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zander</surname>, <given-names>R.</given-names></string-name>, <string-name><surname>Schauder</surname>, <given-names>D.</given-names></string-name>, <string-name><surname>Xin</surname>, <given-names>G.</given-names></string-name>, <string-name><surname>Nguyen</surname>, <given-names>C.</given-names></string-name>, <string-name><surname>Wu</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Zajac</surname>, <given-names>A.</given-names></string-name>, and <string-name><surname>Cui</surname>, <given-names>W</given-names></string-name></person-group>. (<year>2019</year>). <article-title>CD4(+) T Cell Help Is Required for the Formation of a Cytolytic CD8(+) T Cell Subset that Protects against Chronic Infection and Cancer</article-title>. <source>Immunity</source> <volume>51</volume>, <fpage>1028</fpage>–<lpage>1042.</lpage> </mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>, <given-names>P.</given-names></string-name>, <string-name><surname>Chen</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>He</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Zheng</surname>, <given-names>T.</given-names></string-name>, <string-name><surname>Yunis</surname>, <given-names>J.</given-names></string-name>, <string-name><surname>Makota</surname>, <given-names>V.</given-names></string-name>, <string-name><surname>Alexandre</surname>, <given-names>Y.O.</given-names></string-name>, <string-name><surname>Gong</surname>, <given-names>F.</given-names></string-name>, <string-name><surname>Zhang</surname>, <given-names>X.</given-names></string-name>, <string-name><surname>Xie</surname>, <given-names>W.</given-names></string-name>, <etal>et al.</etal></person-group> (<year>2021</year>). <article-title>Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus</article-title>. <source>PLoS Pathog</source> <volume>17</volume>, <fpage>e1009858</fpage>.</mixed-citation></ref>
</ref-list>
</back>
<sub-article id="sa0" article-type="editor-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.99084.1.sa2</article-id>
<title-group>
<article-title>eLife Assessment</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lauvau</surname>
<given-names>Gregoire</given-names>
</name>
<role specific-use="editor">Reviewing Editor</role>
<aff>
<institution-wrap>
<institution>Albert Einstein College of Medicine</institution>
</institution-wrap>
<city>Bronx</city>
<country>United States of America</country>
</aff>
</contrib>
</contrib-group>
<kwd-group kwd-group-type="evidence-strength">
<kwd>Solid</kwd>
</kwd-group>
<kwd-group kwd-group-type="claim-importance">
<kwd>Valuable</kwd>
</kwd-group>
</front-stub>
<body>
<p>This paper provides <bold>valuable</bold> findings related to the impact and timing of exogenous interleukin 2 on the balance of exhausted (Tex) versus effector (Teff) that differentiate from precursors T cells (Tpex) during chronic viral infection. While the data appear <bold>solid</bold>, the overall claims that IL-2 suppresses Tpex are only partially supported, with the rationale for the timing of IL-2 treatment and its underlying mechanisms remaining unclear.</p>
</body>
</sub-article>
<sub-article id="sa1" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.99084.1.sa1</article-id>
<title-group>
<article-title>Reviewer #1 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>Summary:</p>
<p>The title states &quot;IL-2 enhances effector function but suppresses follicular localization of CD8+ T cells in chronic infection&quot; which data from the paper show but does not seem to be the major goal of the authors. As stated in the short assessment above, the goal of this work seems to connect IL-2 signals, mostly given exogenously, to the differentiation of progenitor T cells (TPEX) that will help sustain effector T cell responses against chronic viral infection (TEX/TEFF). The authors mostly use chronic LCMV infection in mice as their model of choice, Flow cytometry, fluorescent microscopy, and some in vitro assays to explore how IL2 regulates TPEX and TEX/TEFF differentiation. Gain and loss of functions experiments are also conducted to explore the roles of L2 signaling and BLIMP-1 in regulating these processes. Lastly, a loose connection of their mouse findings on TPEX/TEX cells to a clinical study using low-dose IL-2 treatment in SLE patients is attempted.</p>
<p>Strengths:</p>
<p>(1) The impact of IL-2 treatment of TPEX/TEX differentiation is very clear.</p>
<p>(2) The flow cytometry data are convincing and state-of-the-art.</p>
<p>Weaknesses:</p>
<p>(1) The title appears disconnected from the major focus of the work.</p>
<p>(2) The number of TPEX cells is not changed. IL2 treatment increases the number of TEFF and the proportion of TPEX is lower suggesting it does not target TPEX formation. The conclusion about an inhibitory role of IL2 treatment on TPEX formation seems therefore largely overstated.</p>
<p>(3) Are the expanded TEX/TEFF cells really effectors? Only GrB and some cell surface markers are monitored (44, 62L). Other functions should be included, e.g., CD107a, IFNg, TNF, chemokines - Tbet?</p>
<p>(4) The rationale for IL2 treatment timing is unclear. Seems that this is given at the T cell contraction time and this is interesting compared to the early treatment that ablate TPEX generation. Maybe this should really be explored further?</p>
<p>(5) The TGFb/IL6/IL2 in vitro experiment does not bring much to the paper.</p>
<p>(6) The Figure 2 data try to provide an explanation for a prior lack of difference in viral titers after IL2 treatment. It is hard to be convinced by these tissue section data as presented. It also begs the question of how the host would benefit from the low dose IL-2 treatment if IL-2 TEFF are not contributing to viral control as a result of their inappropriate localization to viral reservoirs.</p>
<p>(7) It is unclear what the STA5CA and BLIMP-1 KO experiments in Figure 3 add to the story that is not already expected/known.</p>
<p>(8) The connection to the low-dose IL2 treatment in SLE patients is very loose and weak. This version is likely not the ligand that preferentially signals to CD122 either. SLE is different from a chronic viral infection and the question of timing seems critical from all the data shown in this manuscript. So it is very difficult to make any robust link to the mechanistic data.</p>
<p>(9) It is really unclear what the take-home message is. IL-2 is signaling via STAT5 and BLIMP1 is also a known target as published by many groups including this one, and these results are more than expected. The observation that TEFF may be differentially localized in the WP area is interesting but no mechanisms are really provided (guessing CXCR5 but again expected). Also, all these observations are highly dependent on the timing of IL2 administration which is fascinating but not explored at all. It also limits significance since underlying mechanisms are unknown and we do not know when such treatment would have to be given.</p>
</body>
</sub-article>
<sub-article id="sa2" article-type="referee-report">
<front-stub>
<article-id pub-id-type="doi">10.7554/eLife.99084.1.sa0</article-id>
<title-group>
<article-title>Reviewer #2 (Public Review):</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<anonymous/>
<role specific-use="referee">Reviewer</role>
</contrib>
</contrib-group>
</front-stub>
<body>
<p>This study utilized the LCMV Docile infection model, which induces chronic and persistent infection in mice, leading to T cell exhaustion and dysfunction. Through exogenous IL-2 fusion protein treatment during the late stage of infection, the researchers found that IL-2 treatment significantly enlarges the antigen-specific effector CD8 T cells, expanding the CXCR5-TCF1- exhausted population (Tex) while maintaining the size of the CXCR5+TCF1+ precursors of exhausted T cell population (Tpex). This preservation of the Tpex population's self-renewing capacity allows for sustained T cell proliferation and antiviral responses.</p>
<p>The authors discovered a dual effect of IL-2 treatment: it decreases CXCR5 expression on Tpex cells, restricting their entry into the B cell follicle. This may explain why IL-2 treatment has little impact on overall viral control. However, this finding also suggests a potential application of IL-2 treatment for autoimmune diseases, as it can suppress specific immune responses within the B cell follicle. Using imaging-based approaches, the team provided direct evidence that IL-2 treatment shifts the viral load to concentrate within the B cell follicle, correlating with the observed decrease in CXCR5 expression.</p>
<p>Further, the researchers showed that ectopic expression of constitutively active STAT5, downstream of IL-2 induced cytokine signaling, in P14 TCR transgenic T cells (specific for an LCMV epitope), drove the T cell population toward the CXCR5- Tex phenotype over the CXCR5+ Tpex cells in vivo. Additionally, abrogating Blimp1, upregulated by active IL-2-phosphorylated STAT5 signaling, restored the CXCR5+ Tpex population.</p>
<p>Building on these results, the researchers used an engineered IL-2 fusion protein, ANV410, targeting the beta-chain of the IL-2 receptor CD122, which successfully replicated their earlier findings. Importantly, the Tpex-sustaining effect of IL-2 was only observed when treatment was administered during the late stage of infection, as early treatment suppressed Tpex cell generation. Immune profiling of SLE patients undergoing low-dose IL-2 treatment showed a similar reduction in the CXCR5+ Tpex cell population.</p>
<p>This study provides compelling data on the physiological consequences of IL-2 treatment during chronic viral infection. By leveraging the chronic and persistent LCMV Docile infection model, the researchers identified the temporal effects of IL-2 fusion protein treatment, offering strategic insights for therapies targeting cancer and autoimmune diseases.</p>
</body>
</sub-article>
</article>